RESCAP® (RESCuing Alkaline Phosphatase) is the proprietary name for our medication based on the enzyme alkaline phosphatase (AP).
AP is naturally present in the body and is part of the innate immune system (‘first line of defence’). Inflammation, induced by the release of inflammation triggering molecules like ATP from damaged cells and other, sharply increases under traumatic/hypoxic conditions and causes organ damage.
Alkaline phosphatase detoxifies these inflammatory molecules. RESCAP® intervention has the potential to prevent inflammation, to prevent and restore leaky boundaries and to prevent ischemia-induced organ damage and therefore restores the normal homeostasis and thus accelerates recovery of patients in the ICU.
Inflammation, induced by the release of ATP and other inflammation triggering moieties, sharply increases under conditions needing critical care and causes organ damage.
Under critical care conditions, the levels of Alkaline phosphatase in the blood sharply decreases, leading to inflammatory organ damage.
Alkaline phosphatase, an enzyme naturally present in the blood and on physiological barrier systems, detoxifies these inflammatory moieties.
Supplementing the ‘self’ alkaline phosphatase with RESCAP® prevents the critical care related organ damage and inflammation and therefore restores the normal homeostasis.
Like a lifebuoy prevent drowning, RESCAP® prevents and treats complications in patients in need of critical care medicine.
Numerous studies conducted on animals and hundreds of patients have unequivocally demonstrated the safety of alkaline phosphatase, with no reported side effects from intravenous dosing. This is expected, given that alkaline phosphatase is a natural constituent of the human body.
Cardiothoracic surgery is a complex procedure that carries inherent risks, one of which is the potential disruption of kidney function. A significant number of patients undergoing such surgeries have historically experienced complications related to acute kidney injury.
Alloksys has initiated several clinical trials and clinical investigator-initiated trials in critical care medicine , e.g. in major surgery such as CABG (Coronary artery bypass surgery) and solid organ transplantation, and burn trauma
Intestinal Alkaline phosphatase is dosed intravenously from a sterile solution in vials which contain alkaline phosphatase dissolved in a stabilizing buffer.
The invention of alkaline phosphatase as a health relevant enzyme
Poelstra, K., Bakker, W.W., Klok, P.A., Kamps, J.A., Hardonk, M.J. and Meijer, D.K., 1997. Dephosphorylation of endotoxin by alkaline phosphatase in vivo. The American journal of pathology, 151(4), p.1163.
Patient studies with RESCAP: Possible therapeutic strategies
Kats, S., Schönberger, J.P., Brands, R., Seinen, W. and van Oeveren, W., 2011. Endotoxin release in cardiac surgery with cardiopulmonary bypass: pathophysiology and possible therapeutic strategies. An update. European journal of cardio-thoracic surgery, 39(4), pp.451-458.
Patient studies with RESCAP: Safety and efficacy data
Keizer, H., Kats, S., Christis, I., Heylen, R., Oosting, R., Seinen, W. and Brands, R., Safety and efficacy data of a randomized, double-blind, placebo-controlled phase II study with the biological response modifier “bRESCAP” in patients undergoing cardiac surgery (APPIRED II).
Supportive literature on the potential of RESCAP® (alkaline phosphatase)
Kaliannan, K., Hamarneh, S.R., Economopoulos, K.P., Nasrin Alam, S., Moaven, O., Patel, P., Malo, N.S., Ray, M., Abtahi, S.M., Muhammad, N. and Raychowdhury, A., 2013. Intestinal alkaline phosphatase prevents metabolic syndrome in mice. Proceedings of the National Academy of Sciences, 110(17), pp.7003-7008.
Supportive literature on the potential of RESCAP® (alkaline phosphatase)
Kühn, F., Adiliaghdam, F., Cavallaro, P.M., Hamarneh, S.R., Tsurumi, A., Hoda, R.S., Munoz, A.R., Dhole, Y., Ramirez, J.M., Liu, E. and Vasan, R., 2020. Intestinal alkaline phosphatase targets the gut barrier to prevent aging. JCI insight, 5(6).
Supportive literature on the potential of RESCAP® (alkaline phosphatase)
Pickkers, P., Heemskerk, S., Schouten, J., Laterre, P.F., Vincent, J.L., Beishuizen, A., Jorens, P.G., Spapen, H., Bulitta, M., Peters, W.H. and van der Hoeven, J.G., 2012. Alkaline phosphatase for treatment of sepsis-induced acute kidney injury: a prospective randomized double-blind placebo-controlled trial. Critical care, 16, pp.1-12.
Supportive literature on the potential of RESCAP® (alkaline phosphatase)
Davidson, J.A., Khailova, L., Treece, A., Robison, J., Soranno, D.E., Jaggers, J., Ing, R.J., Lawson, S. and Lujan, S.O., 2019. Alkaline phosphatase treatment of acute kidney injury in an infant piglet model of cardiopulmonary bypass with deep hypothermic circulatory arrest. Scientific reports, 9(1), p.14175.
Supportive literature on the potential of RESCAP® (alkaline phosphatase)
Heemskerk, S., Masereeuw, R., Moesker, O., Bouw, M.P., van der Hoeven, J.G., Peters, W.H., Russel, F.G., Pickkers, P. and APSEP Study Group, 2009. Alkaline phosphatase treatment improves renal function in severe sepsis or septic shock patients. Critical care medicine, 37(2), pp.417-e1.
Supportive literature on the potential of RESCAP® (alkaline phosphatase)
Santos, G.M., Ismael, S., Morais, J., Araújo, J.R., Faria, A., Calhau, C. and Marques, C., 2022. Intestinal alkaline phosphatase: A review of this enzyme role in the intestinal barrier function. Microorganisms, 10(4), p.746.
Supportive literature on the potential of RESCAP® (alkaline phosphatase)
Adiliaghdam, F., Cavallaro, P., Mohad, V., Almpani, M., Kühn, F., Gharedaghi, M.H., Najibi, M., Rahme, L.G. and Hodin, R.A., 2020. Targeting the gut to prevent sepsis from a cutaneous burn. JCI insight, 5(19).
Supportive literature on the potential of RESCAP® (alkaline phosphatase)
Kahrovic, A., Poschner, T., Schober, A., Angleitner, P., Alajbegovic, L., Andreas, M., Hutschala, D., Brands, R., Laufer, G., & Wiedemann, D. 2023. “Increased Drop in Activity of Alkaline Phosphatase in Plasma from Patients with Endocarditis.” Int. J. Mol. Sci. 24(14): 11728.
Supportive literature on the potential of RESCAP® (alkaline phosphatase)
Presbitero, A, E.Mancini, R.Brands, V.Krzhizhanovskaya, P. Sloot, Supplemented Alkaline Phosphatase Supports the Immune Response in Patients Undergoing Cardiac Surgery: Clinical and Computational Evidence Front. Immunol., 11 October 2018.
Supportive literature on the potential of RESCAP® (alkaline phosphatase)
Anne-Kristin Schaefer, Doris Hutschala, Martin Andreas, Martin Bernardi, Ruud Brands, Shiva Shabanian, Günther Laufer, Dominik Wiedemann. Decrease in serum alkaline phosphatase and prognostic relevance in adult cardiopulmonary bypass. Interactive CardioVascular and Thoracic Surgery (2020) 1–8.
Supportive literature on the potential of RESCAP® (alkaline phosphatase)
Supportive literature on the potential of RESCAP® (alkaline phosphatase)
Vu T, Fricke TA, Smith JA. A Review of Alkaline Phosphatase in Preventing Systemic Inflammation after Cardiac Surgery. European Journal of Respiratory Medicine. 2021; 3:2.
Supportive literature on the potential of RESCAP® (alkaline phosphatase)
Thei S.Steenvoorden,Janneke A.J.Rood, Frederike J.Bemelman, Roberto Armstrong Jr., Henri G.D.Leuvenink, Joost W.van der Heijden and Liffert Vogt
Supportive literature on the potential of RESCAP® (alkaline phosphatase)
Thei S. Steenvoorden, Robert E. van Duin, Janneke A. J. Rood, Hessel Peters-Sengers, Azam S. Nurmohamed, Frederike J. Bemelman, Liffert Vogt, Joost W. van der Heijden
Alloksys Life Sciences is a pioneering company in the field of alkaline phosphatase-based medical treatments for critical care patients.